AuriGen SIGNED
Next Generation Left Atrial Appendage Implant to Treat Persistent Atrial Fibrillation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0AuriGen project word cloud
Explore the words cloud of the AuriGen project. It provides you a very rough idea of what is the project "AuriGen" about.
Project "AuriGen" data sheet
The following table provides information about the project.
| Coordinator |
AURIGEN MEDICAL LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.aurigenmedical.com |
| Total cost | 3˙503˙093 € |
| EC max contribution | 2˙452˙165 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-07-01 to 2020-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AURIGEN MEDICAL LIMITED | IE (DUBLIN) | coordinator | 2˙452˙165.00 |
Map
Project objective
Atrial Fibrillation (AF) is an irregular heartbeat that can lead to blood clots, high risk of stroke and heart failure. AF is caused by abnormal electrical activity in the heart. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF). Surgical treatment for AF is a minimally invasive electrical therapy which destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients.
We have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. EU and US PAF represents a $5bn/yr market opportunity. We will enter the market directly in our target Tier 1 European markets (Germany, France, Italy and UK). We will scale using specialist distributors to expand into further European, US and other international markets.
In this Phase 2 we will complete the technical, pre-clinical and first in human clinical studies required to achieve CE approval in Europe as well as market development work for commercial launch.
Deliverables
| Sales Director Appointed | Other | 2019-11-25 12:36:59 |
| Operations Director Appointed | Other | 2019-11-25 12:36:58 |
Take a look to the deliverables list in detail: detailed list of AuriGen deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIGEN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "AURIGEN" are provided by the European Opendata Portal: CORDIS opendata.